Agilent Technologies Inc. Collaborates with Wellcome Trust Sanger Institute and Gencode to Develop Latest Human All Exon Target Enrichment Tool for Next-Gen Sequencing

SANTA CLARA, Calif. & CAMBRIDGE, England--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE:A) today introduced the SureSelect Human All Exon 50 Mb Target Enrichment kit for next-generation DNA sequencing. The kit enables researchers to streamline experiments by sequencing the expressed genome while discarding regions that are not of interest.